Interim results of a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISH-amplified advanced or metastatic breast cancer

被引：0
作者：
Stein, S. H.
Gomez, H. L.
Chavez, M. A.
Doval, D. C.
Chow, L. W.
Newstat, B.
Berger, M. S.
Sledge, G. W.
机构：
[1] GlaxoSmithKline Inc, Med Dev Ctr Oncol, Collegeville, MN USA
[2] Inst Special Enfermedades Neoplasica, Lima, Peru
[3] Hosp Alberto Sabogal, Lima, Peru
[4] Rajiv Gandhi Canc Inst, Res Ctr, New Delhi, India
[5] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[6] Indiana Univ, Indianapolis, IN 46204 USA
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：78 / 78
页数：1
相关论文
共 50 条
[31]   Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer:: Results of a multicenter phase II study [J].
Palmeri, S ;
Vaglica, M ;
Spada, S ;
Filippelli, G ;
Farris, A ;
Palmeri, L ;
Massidda, B ;
Misino, A ;
Ferraù, F ;
Comella, G ;
Leonardi, V ;
Condemi, G ;
Mangiameli, A ;
De Cataldis, G ;
Macaluso, MC ;
Cajozzoo, M ;
Iannitto, E ;
Danova, M .
ONCOLOGY, 2005, 68 (4-6) :438-445
[32]   A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer [J].
LaBonte, Melissa J. ;
Yang, Dongyun ;
Zhang, Wu ;
Wilson, Peter M. ;
Nagarwala, Yasir M. ;
Koch, Kevin M. ;
Briner, Colleen ;
Kaneko, Tomomi ;
Rha, Sun-Young ;
Gladkov, Oleg ;
Urba, Susan G. ;
Sakaeva, Dina ;
Pishvaian, Michael J. ;
Hsieh, Ruey-Kuen ;
Lee, Wei-Ping ;
Lenz, Heinz-Josef .
MOLECULAR CANCER THERAPEUTICS, 2016, 15 (09) :2251-2258
[33]   First-line treatment for metastatic colorectal cancer (MCRC) patients (pts). Results of a randomized phase IIITMO study [J].
Bajetta, E. ;
Di Bartolomeo, M. ;
Ferrario, E. ;
Beretta, E. ;
Rabbi, C. ;
Isa, L. ;
Barone, C. ;
Lo, S. ;
Zilembo, Vullo N. .
ANNALS OF ONCOLOGY, 2005, 16 :48-48
[34]   TEGAFIRI and TEGAFOX as an effective first-line treatment for metastatic colorectal cancer patients: Randomized phase II study [J].
Bajetta, E. ;
Di Bartolomeo, M. ;
Buzzoni, R. ;
Ferrario, E. ;
Jacobelli, S. ;
Recaldin, E. ;
Pinotti, G. ;
Iop, A. .
ANNALS OF ONCOLOGY, 2006, 17 :XI47-XI47
[35]   A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients. [J].
Chu, Q ;
Goldstein, L ;
Murray, N ;
Rowinsky, E ;
Cianfrocca, M ;
Gale, M ;
Ho, P ;
Paul, E ;
Loftiss, J ;
Pandite, L .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :192S-192S
[36]   Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer [J].
Guerrero, Antonio ;
Servitja, Sonia ;
Rodriguez-Lescure, Alvaro ;
Calvo, Lourdes ;
del Barco, Sonia ;
Teresa Quintanar, Maria ;
Ignacio Juarez, Jose ;
Gayo, Javier ;
Llombart, Antonio ;
Tusquets, Ignasi .
ANTI-CANCER DRUGS, 2011, 22 (03) :283-289
[37]   Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients [J].
Di Leo, A. ;
Gomez, H. ;
Aziz, Z. ;
Zvirbule, Z. ;
Arbushites, M. ;
Oliva, C. R. ;
Koehler, M. ;
Williams, L. S. ;
Dering, J. ;
Finn, R. S. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[38]   Phase II study of vinorelbine and capecitabine as first-line treatment for metastatic breast cancer. [J].
El-Sadda, Wael ;
Halim, Inas Ibraheim Abdel ;
Aziz, Mohamed Abdel .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[39]   Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer [J].
Luck, HJ ;
Thomssen, C ;
duBois, A ;
Untch, M ;
Lisboa, B ;
Kohler, G ;
Diergarten, K .
SEMINARS IN ONCOLOGY, 1997, 24 (05) :35-39
[40]   A phase II study of lapatinib and capecitabine in first-line treatment of metastatic pancreatic cancer (ICORG 08-39) [J].
McDermott, R. S. ;
Calvert, P. ;
Parker, M. ;
Webb, G. ;
Moulton, B. ;
McCaffrey, J. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345